Purpose / DescriptionSURVEYOR-I (for genotypes 1, 4, 5 and 6) and SURVEYOR-II (genotypes 2 and 3) were both phase 2 open-label trials of non-cirrhotic treatment-naïve and treatment experienced adults. Part 1 of each study evaluated the efficacy of various doses of glecaprevir-pibrentasvir for 12 weeks and Part 2 examined the optimized dose of 300/120 mg for 8 versus 12 weeks. The dose-ranging studies (Part 1) confirmed that 300/120 mg of glecaprevir-pibrentasvir had high efficacy across the genotypes (96-100%) and that the addition of ribavirin in genotype 2 or 3 did not appear to be associated with any difference in response. In Part 2, there were no virologic failures among the 203 treatment-naïve patients who received either 8 or 12 weeks of glecaprevir-pibrentasvir 300/120 mg. There were, however, two relapses and one breakthrough among the 27 patients with genotype 3 who were peginterferon and ribavirin-experienced.